Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
Ying LiuJacquelyn BainbridgeStefan SillauSarah N FischerMichelle AdkinsChristopher H DomenJohn A ThompsonTristan SeawaltJost KlawitterCristina SempioGrace ChinLisa FormanMichelle FullardTrevor HawkinsLauren SeebergerHeike NewmanDavid VuMaureen Anne LeeheyPublished in: Movement disorders : official journal of the Movement Disorder Society (2024)
The brief duration and strong placebo response limits interpretation of effects, but there was no benefit, perhaps worsened cognition and sleep, and there was many mild adverse events. Longer duration high quality trials that monitor cannabinoid concentrations are essential and would require improved availability of research cannabinoid products in the United States. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.